Rao SM, Galioto R, Sokolowski M, et al. - In this investigation involving 30 multiple sclerosis (MS) patients and 30 healthy controls, researchers analyzed the test-retest reliability, practice impacts, convergent validity and sensitivity to MS disability of neuroperformance subtests from the patient self-administered Multiple Sclerosis Performance Test (MSPT) designed to evaluate low contrast vision (Contrast Sensitivity Test, CST), upper extremity motor function (Manual Dexterity Test, MDT) and lower extremity motor function (Walking Speed Test, WST). In addition, they introduced the concept of regression-based norms to assist clinical interpretation of performance scores utilizing the MSPT cognition test (Processing Speed Test, PST) as an example. It has been shown that the CST, MDT, and WST are reliable, valid and sensitive to MS outcomes. Performance was similar to technician-administered testing. The self-administered MSPT neuroperformance modules generate accurate, objective measures that can be used in clinical practice and support research outcomes. Published studies that involve voluntary consent from the patient can underestimate the rate of cognitive dysfunction found in a clinical setting.